Cubist shelves ecallantide program

Cubist Pharmaceuticals is shelving its program for ecallantide, a once promising therapy for reducing blood loss in surgery, and axing its development deal on the drug with Dyax. The troubled program was suspended in mid-stage late last year after researchers spotted a higher death rate among patients taking the drug. Story